Breaking News

Genisphere Expands LIMR Pact

November 30, 2012

To develop nanotherapeutics targeting cancers and eye diseases

Genisphere and the Lankenau Institute for Medical Research (LIMR) have partnered to develop nanotherapeutics targeting cancers and eye diseases. This partnership expands an existing collaboration to identify inflammatory bowel disease biomarkers.
 
Genisphere will use its 3DNA dendrimer, which allows researchers to deliver a therapeutic agent to any target cell. It is manufactured from natural strands of DNA hybridized together to create high biocompatibility and low toxicity. With the dendrimer technology, LIMR researchers are using targeted drug delivery to treat ovarian, cervical, prostate and pancreatic cancer, as well as a therapy that uses small molecule drugs to target cells that cause post-cataract surgery eye lesions.
 
"LIMR is fortunate to partner with Genisphere for the development of its cancer nanotherapies,” said George Prendergast, Ph.D., president and chief executive officer of LIMR. “Given the wonderful intersection of these two organizations, we will have the right tools and skill sets to strengthen the path forward for clinical testing and ultimately commercialization."
 
“LIMR, with its team of talented scientists, is an ideal partner for us to study how certain therapeutics work with our DNA dendrimer nanoparticles,” said Bob Getts, chief science officer of Genisphere.

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016